For individuals without T2D, semaglutide 2.4 mg once weekly resulted in a body weight reduction of 12.4% relative to placebo (treatment policy estimand) after 68 weeks (STEP-1 trial) again lower than the 17.8% relative to placebo reported in the SURMOUNT-1 trial with tirzepatide with only 4 weeks longer treatment duration
Recovery capacity may be somewhat reduced during aggressive dieting, making every-other-day training or a Monday/Wednesday/Friday schedule work well for many users
Farook VS, Reddivari L, Chittoor G, Puppala S, Arya R, Fowler SP, et al
Side effects may include gastrointestinal upset, headache, or changes in appetite
Nevertheless, this increase was only 1.47%, which may be acceptable to most patients, given the weight loss and cardiovascular benefits associated with semaglutide treatment
Some of Struts prices here are favorable, while others fall short